Comparison of the efficacy of domestic and imported versions of lenvatinib/lenvatinib

Lenvatinib is a multi-target tyrosine kinase inhibitor that is widely used to treat multiple types of cancer, including renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and endometrial cancer. Its main function is to prevent tumor cell proliferation and angiogenesis by inhibiting multiple tyrosine kinases related to tumor growth, such as VEGFR, FGFR, PDGFR and KIT, thereby inhibiting tumor growth.

There are almost no differences in drug ingredients and basic mechanism of action between the domestic and imported versions of lenvatinib. Both contain the same active ingredient - lenvatinib, and their mechanism of action, efficacy and safety have been fully proven. Whether it is imported drugs or domestic drugs, their clinical effects have shown good efficacy in the treatment of multiple cancer types. Especially in the treatment of advanced liver cancer, thyroid cancer and renal cell carcinoma, the effect of lenvatinib has been widely recognized. Whether it is the imported version or the domestic version, its pharmacological effects are almost the same. They control tumor growth and reduce tumor metastasis by inhibiting angiogenesis and tumor cell proliferation.

However, although the efficacy of the two is basically the same, due to different manufacturers, there is a significant difference in price between domestically produced lenvatinib and imported lenvatinib. Domestic versions usually have more advantageous prices, making domestic drugs a viable option for some patients with relatively poor economic conditions. In addition to price, some patients may experience minor side effects when using domestic drugs, but the frequency and severity of these side effects are not significantly different from imported drugs.

Clinically, the difference in efficacy between imported and domestic lenvatinib is minimal, and most patients can obtain similar therapeutic effects when using these two drugs. Therefore, from the perspective of efficacy, the domestic version and the imported version are almost interchangeable, and patients can choose according to their own financial situation and doctor's recommendations.

Reference materials:https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206947s021lbl.pdf